Clinical guideline recommends avoiding cannabis during pregnancy and breastfeeding

A Canadian clinical guideline concluded cannabis use during pregnancy and breastfeeding should be avoided given limited safety data, while emphasizing screening, supportive communication, and harm reduction if abstaining is not feasible.

RTHC-03884ReviewModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Based on GRADE-assessed evidence, the guideline recommends avoiding cannabis during pregnancy and breastfeeding, or reducing use as much as possible if abstaining is not feasible. Key focus areas include screening, dependence and withdrawal management, communication approaches, maternal/fetal outcomes, pain control, postpartum care including secondhand smoke, and breastfeeding considerations.

Key Numbers

Literature search covered January 2018 to February 2021. Guideline addresses screening, dependence, withdrawal, communication, maternal/fetal outcomes, pain control, postpartum care, and breastfeeding.

How They Did This

Clinical practice guideline searching PubMed and Cochrane for articles published January 2018 to February 2021. Included clinical trials, observational studies, reviews, and guidelines on cannabis during pregnancy and breastfeeding. Evidence quality rated using GRADE.

Why This Research Matters

Cannabis use during pregnancy is increasing. Clinicians need evidence-based guidelines to counsel patients, particularly as social acceptability of cannabis grows.

The Bigger Picture

The guideline takes a harm reduction approach: rather than simply advising against use, it provides strategies for reducing harm when complete abstinence is not achievable.

What This Study Doesn't Tell Us

Limited high-quality evidence available. Most studies are observational with potential confounders. Long-term follow-up data on cannabis-exposed pregnancies is sparse.

Questions This Raises

  • ?What are the specific dose-response relationships between cannabis exposure during pregnancy and fetal outcomes?
  • ?Are some formulations or routes of administration less harmful?

Trust & Context

Key Stat:
Recommends avoidance or maximum reduction if abstaining not feasible
Evidence Grade:
GRADE-assessed clinical guideline, but underlying evidence is largely observational with limited long-term data.
Study Age:
Published in 2022 with literature through February 2021.
Original Title:
Guideline No. 425b: Cannabis Use Throughout Women's Lifespans - Part 2: Pregnancy, the Postnatal Period, and Breastfeeding.
Published In:
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 44(4), 436-444.e1 (2022)
Database ID:
RTHC-03884

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Should cannabis be completely avoided during pregnancy?

The guideline recommends avoidance based on limited safety data. If abstaining is not feasible, reducing use as much as possible is recommended as a harm reduction approach.

What about cannabis and breastfeeding?

The guideline also recommends avoiding cannabis during breastfeeding, given the absence of safety data on long-term effects of cannabis exposure through breast milk.

Read More on RethinkTHC

Cite This Study

RTHC-03884·https://rethinkthc.com/research/RTHC-03884

APA

Graves, Lisa E; Robert, Magali; Allen, Victoria M; Dama, Sumeet; Gabrys, Robert L; Tanguay, Robert L; Turner, Suzanne D; Green, Courtney R; Cook, Jocelynn L. (2022). Guideline No. 425b: Cannabis Use Throughout Women's Lifespans - Part 2: Pregnancy, the Postnatal Period, and Breastfeeding.. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 44(4), 436-444.e1. https://doi.org/10.1016/j.jogc.2022.01.013

MLA

Graves, Lisa E, et al. "Guideline No. 425b: Cannabis Use Throughout Women's Lifespans - Part 2: Pregnancy, the Postnatal Period, and Breastfeeding.." Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2022. https://doi.org/10.1016/j.jogc.2022.01.013

RethinkTHC

RethinkTHC Research Database. "Guideline No. 425b: Cannabis Use Throughout Women's Lifespan..." RTHC-03884. Retrieved from https://rethinkthc.com/research/graves-2022-guideline-no-425b-cannabis

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.